Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma - Related Studies

Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

This study has been suspended.

Study NCT00474929. Last updated on November 16, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Lymphoma

2	Additional conditions recognized in this trial
		Hodgkin Disease
		Lymphoma, Non-Hodgkin
		Multiple Myeloma
		Neoplasms, Plasma Cell

3	More general conditions related to this trial
		Blood Protein Disorders
		Cardiovascular Diseases
		Hematologic Diseases
		Hemorrhagic Disorders
		Hemostatic Disorders
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphatic Diseases
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type
		Paraproteinemias
		Vascular Diseases

4	Interventions listed in this trial
		everolimus
		sorafenib tosylate
		flow cytometry
		immunoenzyme technique
		pharmacological study

5	Additional drug interventions recognized in this trial
		Sorafenib

6	More general drug interventions related to this trial
		Antineoplastic Agents
		Enzyme Inhibitors
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Protein Kinase Inhibitors
		Therapeutic Uses

7	Sponsors listed in this trial
		Mayo Clinic
		National Cancer Institute (NCI)